Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Menen – page 66

1 845 clinical trials in Menen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Menen at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Menen

Open in trial search

Antiphospholipid syndrome

Not yet recruiting

Stopping warfarin sodium, fluindione, or acenocoumarol in low‑risk thrombotic antiphospholipid syndrome patients after antibody loss

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Assistance Publique Hopitaux De Paris

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Crohn's disease

Not yet recruiting

Clinical trial of subcutaneous infliximab in patients with perianal fistulizing Crohn’s disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:CHU De Liege

Chronic lymphocytic leukaemia+1

Not yet recruiting

Phase II Study of Zanubrutinib in Elderly, Treatment‑Naïve Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Zanubrutinib
  • Sponsor:LYSARC

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Colitis ulcerative

Not yet recruiting

Evaluation of Upadacitinib Re‑induction in Patients with Ulcerative Colitis Who Have Lost Response to a 30 mg Maintenance Dose

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:i-GETAID

Retinoblastoma

Not yet recruiting

Carboplatin with drug combination for children with unilateral retinoblastoma undergoing enucleation: study of tumor biomarkers and relapse risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Phase 2 Study of Apitegromab in Patients with Facioscapulohumeral Muscular Dystrophy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Apitegromab
  • Sponsor:Scholar Rock Inc.

Reducing abemaciclib, palbociclib and ribociclib after complete response in HER2‑negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Menen

What the registry says about research in the country

01 Advanced Lung Cancer Research

Investigating innovative treatments for Non-Small Cell Lung Cancer (NSCLC), with a focus on patients carrying specific genetic mutations like EGFR Exon 20 insertions. The research evaluates combination therapies using zipalertinib with traditional chemotherapy to improve treatment outcomes.

  • Targeted Therapy Development
  • Genetic Mutation Analysis
  • Combination Treatment Strategies

Studies aim to determine optimal dosing and measure progression-free survival rates in advanced cases.

02 Immunotherapy Research

Evaluating the effectiveness of therapeutic cancer vaccines compared to conventional chemotherapy in treating metastatic NSCLC patients. The research specifically focuses on patients with HLA-A2 positive phenotype who have experienced immunotherapy failure.

  • Cancer Vaccine Development
  • Treatment Resistance Studies
  • Overall Survival Analysis

Research aims to demonstrate improved survival outcomes using novel vaccine-based approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.